Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung ...
Sep 12, 2026
0
27
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab ...
Jul 30, 2026
0
9
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration ...
Jul 16, 2026
0
9
Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine ...
Jul 7, 2026
0
8
For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according ...
Jul 2, 2026
0
3
Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically ...
Jul 1, 2026
0
5
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care ...
Jun 15, 2026
0
5
The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations ...
May 29, 2026
0
11
Treating breast cancer that has begun to spread around the body with targeted radiotherapy could help patients to live longer without their cancer getting worse, according to the results of a small randomized controlled trial ...
May 17, 2026
0
17
An international group of experts led by the Comprehensive Cancer Center (CCC) at MedUni Vienna and University Hospital Vienna has established endpoints for clinical trials in patients with cancer and isolated metastases. ...
Apr 28, 2026
0
5
